<!DOCTYPE html><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.6.0 for Hugo" />
  

  
  












  
  










  







  
  

  
  
  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="A highly-customizable Hugo documentation theme powered by Wowchemy website builder." />

  
  <link rel="alternate" hreflang="en-us" href="https://example.com/tag/immunotherapy/" />

  
  
  
    <meta name="theme-color" content="#1565c0" />
  

  
  
    
    <script src="/js/mathjax-config.js"></script>
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.c7b8d9abd591ba2253ea42747e3ac3f5.css" media="print" onload="this.media='all'">

  
  
  
    
    

    
    
    
    
      
      
    
    
    

    
    
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.7579f2ea081d74b9cb40a7d984071feb.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  



  


  


  




  
  
  

  
  
    <link rel="alternate" href="/tag/immunotherapy/index.xml" type="application/rss+xml" title="BM Sci-Tech Memento" />
  

  
  
    <link rel="manifest" href="/manifest.webmanifest" />
  

  
  <link rel="icon" type="image/png" href="/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_32x32_fill_lanczos_center_3.png" />
  <link rel="apple-touch-icon" type="image/png" href="/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_180x180_fill_lanczos_center_3.png" />

  <link rel="canonical" href="https://example.com/tag/immunotherapy/" />

  
  
  
  
  
  
  
  
    
    
  
  

  
  
    
    
  
  <meta property="twitter:card" content="summary" />
  
    <meta property="twitter:site" content="@wowchemy" />
    <meta property="twitter:creator" content="@wowchemy" />
  
  <meta property="og:site_name" content="BM Sci-Tech Memento" />
  <meta property="og:url" content="https://example.com/tag/immunotherapy/" />
  <meta property="og:title" content="Immunotherapy | BM Sci-Tech Memento" />
  <meta property="og:description" content="A highly-customizable Hugo documentation theme powered by Wowchemy website builder." /><meta property="og:image" content="https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png" />
    <meta property="twitter:image" content="https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />
  
    
      <meta property="og:updated_time" content="2022-12-07T00:00:00&#43;00:00" />
    
  

  



  


  <title>Immunotherapy | BM Sci-Tech Memento</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   "  >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.613040fe4f2c0f007b4dcb64404201cb.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header">
    












<header class="header--fixed">
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">BM Sci-Tech Memento</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">BM Sci-Tech Memento</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          

          

          
          
          
          

          
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/"><span>Home</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/tool/"><span>Tools</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/docs/"><span>Notes</span></a>
          </li>

          
          

          

          
          
          
            
              
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank" rel="noopener"><span>PubMed</span></a>
          </li>

          
          

          

          
          
          
            
              
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="https://licore.netlify.app/" target="_blank" rel="noopener"><span>MII</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        

        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        
        <li class="nav-item dropdown theme-dropdown">
          <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
            <i class="fas fa-moon" aria-hidden="true"></i>
          </a>
          <div class="dropdown-menu">
            <a href="#" class="dropdown-item js-set-theme-light">
              <span>Light</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-dark">
              <span>Dark</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-auto">
              <span>Automatic</span>
            </a>
          </div>
        </li>
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    












  

  
  
  
    
  
<div class="universal-wrapper pt-3">
  <h1>Immunotherapy</h1>

  

  
</div>



<div class="universal-wrapper">
  

  
  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/36470333/" >Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies</a>
    </div>

    
    <a href="/article/36470333/"  class="summary-link">
      <div class="article-style">
        Abstract
Therapeutics that discriminate between the genetic makeup of normal cells and tumour cells are valuable for treating and understanding cancer. Small molecules with oncogene-selective lethality may reveal novel functions of oncoproteins and enable the creation of more selective drugs.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Wednesday, 07 December 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  

















<a class="btn btn-outline-primary btn-page-header btn-sm" href="https://doi.org/10.1016/j.jconrel.2022.11.053" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.sciencedirect.com/science/article/abs/pii/S0168365922008070" target="_blank" rel="noopener">
    Journal of Controlled Release</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/36470333/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/36470333/" >
      <img src="/article/36470333/featured_hub28ed4682d468cb3aa96ee75c64acb4e_216740_150x0_resize_q75_h2_lanczos.webp" height="84" width="150"
           alt="Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/36447429/" >Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery</a>
    </div>

    
    <a href="/article/36447429/"  class="summary-link">
      <div class="article-style">
        Abstract
T cell-derived small extracellular vesicles (sEVs) exhibit anti-cancer effects. However, their anti-cancer potential should be reinforced to enhance clinical applicability. Herein, we generated interleukin-2-tethered sEVs (IL2-sEVs) from engineered Jurkat T cells expressing IL2 at the plasma membrane via a flexible linker to induce an autocrine effect.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Tuesday, 29 November 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  

















<a class="btn btn-outline-primary btn-page-header btn-sm" href="https://doi.org/10.1002/jev2.12287" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://onlinelibrary.wiley.com/doi/10.1002/jev2.12287" target="_blank" rel="noopener">
    Journal of Extracellular Vesicles</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/36447429/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/36447429/" >
      <img src="/article/36447429/featured_hu9d7d179328bebb7d41d5cfcca0957b38_329640_150x0_resize_q75_h2_lanczos.webp" height="155" width="150"
           alt="Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/36443756/" >IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction</a>
    </div>

    
    <a href="/article/36443756/"  class="summary-link">
      <div class="article-style">
        Abstract
Background: The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are not targeted by nonsense-mediated mRNA decay (NMD).
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Monday, 28 November 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  

















<a class="btn btn-outline-primary btn-page-header btn-sm" href="https://doi.org/10.1186/s12943-022-01679-6" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-022-01679-6" target="_blank" rel="noopener">
    Molecular Cancer</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/36443756/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703761/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/36443756/" >
      <img src="/article/36443756/featured_hua062bce2af5646392ab77b131ba464e8_117191_150x0_resize_q75_h2_lanczos.webp" height="180" width="150"
           alt="IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/36357792/" >Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy</a>
    </div>

    
    <a href="/article/36357792/"  class="summary-link">
      <div class="article-style">
        Abstract
Solid tumours display a limited response to immunotherapies. By contrast, haematological malignancies exhibit significantly higher response rates to immunotherapies as compared with solid tumours. Among several microenvironmental and biological disparities, the differential expression of unique immune regulatory molecules contributes significantly to the interaction of blood cancer cells with immune cells.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Thursday, 10 November 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  

















<a class="btn btn-outline-primary btn-page-header btn-sm" href="https://doi.org/10.1038/s41565-022-01245-7" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.nature.com/articles/s41565-022-01245-7" target="_blank" rel="noopener">
    Nature Nanotechnology</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/36357792/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/36357792/" >
      <img src="/article/36357792/featured_hucd9cd6fde5cda3fd6519152472431121_212793_150x0_resize_q75_h2_lanczos.webp" height="127" width="150"
           alt="Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/36283801/" >Targeting tumour-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy</a>
    </div>

    
    <a href="/article/36283801/"  class="summary-link">
      <div class="article-style">
        Abstract
Objective Intrahepatic cholangiocarcinoma (ICC) exhibits very low response rate to immune checkpoint inhibitors (ICIs) and the underlying mechanism is largely unknown. We investigate the tumour immune microenvironment (TIME) of ICCs and the underlying regulatory mechanisms with the aim of developing new target to inhibit tumour growth and improve anti-programmed cell death protein-1 (PD-1) efficacy.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Tuesday, 25 October 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://gut.bmj.com/content/early/2022/10/25/gutjnl-2022-327230.long" target="_blank" rel="noopener">
    Gut</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/36283801/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/36283801/" >
      <img src="/article/36283801/featured_hu93c5900b1cafb8845e366f2001cc6842_228214_150x0_resize_q75_h2_lanczos.webp" height="174" width="150"
           alt="Targeting tumour-intrinsic N7-methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/33458695/" >c-Rel Is a Myeloid Checkpoint for Cancer Immunotherapy</a>
    </div>

    
    <a href="/article/33458695/"  class="summary-link">
      <div class="article-style">
        Abstract
Therapy that targets lymphoid cell checkpoints holds great promise for curing cancer. However, a majority of cancer patients do not respond to this form of therapy. In addition to lymphoid cells, myeloid cells play essential roles in controlling immunity to cancer.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Monday, 18 May 2020 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.nature.com/articles/s43018-020-0061-3" target="_blank" rel="noopener">
    Nature Cancer</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/33458695/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808269/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/33458695/" >
      <img src="/article/33458695/featured_hu9d94dbd1451b62bb9621c177a6b2da8c_119311_150x0_resize_q75_h2_lanczos.webp" height="183" width="150"
           alt="c-Rel Is a Myeloid Checkpoint for Cancer Immunotherapy" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/32405063/" >High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade</a>
    </div>

    
    <a href="/article/32405063/"  class="summary-link">
      <div class="article-style">
        Erratum in: can also be found.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Abstract
Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade 1, this has not been comprehensively evaluated in large randomized studies.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Monday, 11 May 2020 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.nature.com/articles/s41591-020-0860-1" target="_blank" rel="noopener">
    Nature Medicine</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/32405063/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286544/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/32405063/" >
      <img src="/article/32405063/featured_hua5e4475d228234b52480f691979275de_417442_150x0_resize_q75_h2_lanczos.webp" height="184" width="150"
           alt="High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade" loading="lazy">
    </a>
    
  </div>
</div>

  

  

</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  

  

  

  
  






  
  <p class="powered-by copyright-license-text">
    Copyright © 2023 | Biomedist | All rights reserved.
  </p>
  




  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  













  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.c251366b4128fd5e6b046d4c97a62a51.js" type="module"></script>








  
  


<script src="/en/js/wowchemy.min.54dd6e4d8f2e4b1d098381b57f18dd83.js"></script>























</body>
</html>
